Drug Profile
Belrestotug - iTeos Therapeutics
Alternative Names: EOS 884448; EOS-448; GSK-4428859; GSK-4428859A; TIGIT antagonist monoclonal antibody - iTeos TherapeuticsLatest Information Update: 19 Jan 2024
Price :
$50
*
At a glance
- Originator iTeos Therapeutics
- Developer GSK; iTeos Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer; Squamous cell cancer
- Phase I/II Haematological malignancies; Multiple myeloma; Solid tumours
Most Recent Events
- 14 Nov 2023 Phase-II clinical trials in Squamous cell cancer (Metastatic disease, Recurrent, Combination therapy, Second-line therapy or greater) in Argentina (Parenteral) (NCT06062420) (EudraCT2023-503428-24-00)
- 14 Nov 2023 Phase-II clinical trials in Squamous cell cancer (Metastatic disease, Recurrent, Combination therapy, Second-line therapy or greater) in Brazil (Parenteral) (NCT06062420) (EudraCT2023-503428-24-00)
- 14 Nov 2023 Phase-II clinical trials in Squamous cell cancer (Metastatic disease, Recurrent, Combination therapy, Second-line therapy or greater) in Canada (Parenteral) (NCT06062420) (EudraCT2023-503428-24-00)